| Today's Big NewsJun 28, 2023 |
| By Max Bayer,Gabrielle Masson The Inflation Reduction Act's drug pricing reforms have sent shock waves through the drug development world, with executives arguing the legislation stands to stymie the development of innovative new medicines. |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Angus Liu Merely a month into an FDA approval, AbbVie and Genmab’s bispecific drug Epkinly has chalked up a positive readout that might enable an expansion in blood cancer, although the exact regulatory path remains unclear. |
By Kevin Dunleavy Pfizer is on an FDA heater. With a blessing Wednesday for once-weekly growth hormone deficiency (GHD) drug Ngenla, the New York pharma giant has racked up four approvals from the agency over the last five weeks. |
By Andrea Park After several weeks of back-and-forth, the proxy battle activist investor Politan Capital Management waged against Masimo has drawn to a close. |
|
Wednesday, July 12, 2023 | 2pm ET/11am PT In this webinar, we will explore how critical it is for life sciences companies to use data to analyze the behavior of cancer at the individual level, uncover new targets and biomarkers for precision therapies, and increase the value of existing oncology drugs to new indications. Register now. 
|
|
By Nick Paul Taylor Bayer has early evidence that its Parkinson’s disease cell therapy is safe. Now, with a phase 2 clinical trial on course to open enrollment next year, the German drugmaker is set to start showing whether the candidate can undo damage and restore motor function. |
By Angus Liu Alexis Borisy, the serial biotech entrepreneur and self-dubbed “man of many hats,” may have to reduce two of his many duties. |
By Andrea Park Tandem Diabetes Care’s insulin pumps already make up more than a third of those used by people with Type 1 diabetes in the U.S., according to Elizabeth Gasser, an executive VP at Tandem and its chief strategy officer—but the company wants an even bigger piece of the pie. |
By James Waldron Foghorn Therapeutics isn’t having much luck with FHD-286. Only weeks after the FDA released a trial of the drug in two blood cancers from a clinical hold, the biotech has abandoned plans for the candidate in an eye tumor after taking a look at phase 1 data. |
By Kevin Dunleavy Paratek Pharmaceuticals' annual meeting is set for July 6, but fireworks are already exploding over the company’s attempt to sell out to investment firms Novo Holdings and Gurnet Point. Activist investor NexPoint Asset Management—which holds 12% of Paratek’s common stock—is trying to detonate the deal. |
By Fraiser Kansteiner After an FDA thumbs up on Reata's approval supplement for Skyclarys, analysts feel confident the newly commercial-stage company can meet—or potentially even exceed—a $45.9 million sales target for 2023. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the most expensive drugs in the U.S., plus Eli Lilly's recent acquisition, the latest company to challenge the Inflation Reduction Act, and the rest of the week's headlines. |
|
|---|
|
|
|
Wednesday, July 12, 2023 | 11:00am ET / 8:00am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now. 
|
|
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
